CRYOPORT, INC. Accounts Receivable, Change in Method, Credit Loss Expense (Reversal)
CRYOPORT, INC. (CYRX) reported Accounts Receivable, Change in Method, Credit Loss Expense (Reversal) of $21.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AccountsReceivableChangeInMethodCreditLossExpenseReversal · last filed 2026-08-06
- CRYOPORT, INC. accounts receivable, change in method, credit loss expense (reversal) for the quarter ending 2025-12-31 was -$141.00K, a 254.95% decline year-over-year.
- CRYOPORT, INC. accounts receivable, change in method, credit loss expense (reversal) for the quarter ending 2025-09-30 was -$83.00K.
- CRYOPORT, INC. accounts receivable, change in method, credit loss expense (reversal) for the quarter ending 2024-12-31 was $91.00K.
- CRYOPORT, INC. accounts receivable, change in method, credit loss expense (reversal) for the quarter ending 2024-09-30 was -$12.00K, a 185.71% decline year-over-year.
| Period end | Accounts Receivable, Change in Method, Credit Loss Expense (Reversal) 3 month | Accounts Receivable, Change in Method, Credit Loss Expense (Reversal) 6 month | Accounts Receivable, Change in Method, Credit Loss Expense (Reversal) 9 month | Accounts Receivable, Change in Method, Credit Loss Expense (Reversal) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $21.00K 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | -$141.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-06 | -$224.00K derived: sum of 2 quarters · filed 2026-08-06 | -$263.00K 10-Q · filed 2026-08-06 | |
| 2025-09-30 | -$83.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$122.00K 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | -$39.00K 10-Q · filed 2025-08-12 | |||
| 2024-12-31 | $91.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2025-11-06 | $79.00K derived: sum of 2 quarters · filed 2025-11-06 | $178.00K derived: sum of 3 quarters · filed 2025-11-06 | -$68.00K 10-Q · filed 2025-11-06 |
| 2024-09-30 | -$12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $87.00K derived: sum of 2 quarters · filed 2024-11-07 | -$159.00K 10-Q · filed 2024-11-07 | -$995.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | $99.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$147.00K 10-Q · filed 2024-08-08 | -$983.00K derived: sum of 3 quarters · filed 2024-11-07 | -$969.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-03-31 | -$246.00K 10-Q · filed 2024-05-08 | -$1.08M derived: sum of 2 quarters · filed 2024-11-07 | -$1.07M derived: sum of 3 quarters · filed 2024-11-07 | -$1.16M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-12-31 | -$836.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2024-11-07 | -$822.00K derived: sum of 2 quarters · filed 2024-11-07 | -$915.00K derived: sum of 3 quarters · filed 2024-11-07 | -$812.00K 10-Q · filed 2024-11-07 |
| 2023-09-30 | $14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$79.00K derived: sum of 2 quarters · filed 2023-11-09 | $24.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | -$93.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $10.00K 10-Q · filed 2023-08-09 | ||
| 2023-03-31 | $103.00K 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |